Pharmacoeconomic review report: Baricitinib (Olumiant) (Eli Lilly Canada Inc.)
Baricitinib (Olumiant) is indicated for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying antirheumatic drugs (DMARDs). The recommended dosage is 2 mg tablet daily. At the submitted price of $47.92 per 2 m...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
September 2019, 2019
|
| Edition: | Version: final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Baricitinib (Olumiant) is indicated for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying antirheumatic drugs (DMARDs). The recommended dosage is 2 mg tablet daily. At the submitted price of $47.92 per 2 mg tablet, the annual cost is $17,490. The manufacturer submitted a cost-effectiveness analysis based on a discrete-event simulation model. The model compares numerous possible sequences of biologic treatments as current practice for the treatment of RA, including changing to a different treatment, often of a different class, when patients fail their current treatment |
|---|---|
| Physical Description: | 1 PDF file (52 pages) illustrations |